Clinical Trial Update: A Study to Observe the Safety and Tolerability of Paliperidone Palmitate (Invega Sustenna) in Korean Schizophrenic Patients

View source ↗

Summary

A completed study assessing the safety and tolerability of paliperidone palmitate (Invega Sustenna) in Korean patients with schizophrenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• INVEGA SUSTENNA (PALIPERIDONE PALMITATE)

Snippet

Sponsor: Janssen Korea, Ltd., Korea | Conditions: Schizophrenia | Status: COMPLETED